Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery and Characterization of ACT-451840: an Antimalarial Drug with a Novel Mechanism of Action.
Boss C, Aissaoui H, Amaral N, Bauer A, Bazire S, Binkert C, Brun R, Bürki C, Ciana CL, Corminboeuf O, Delahaye S, Dollinger C, Fischli C, Fischli W, Flock A, Frantz MC, Girault M, Grisostomi C, Friedli A, Heidmann B, Hinder C, Jacob G, Le Bihan A, Malrieu S, Mamzed S, Merot A, Meyer S, Peixoto S, Petit N, Siegrist R, Trollux J, Weller T, Wittlin S. Boss C, et al. Among authors: weller t. ChemMedChem. 2016 Sep 20;11(18):1995-2014. doi: 10.1002/cmdc.201600298. Epub 2016 Jul 29. ChemMedChem. 2016. PMID: 27471138
Achiral, cheap, and potent inhibitors of Plasmepsins I, II, and IV.
Boss C, Corminboeuf O, Grisostomi C, Meyer S, Jones AF, Prade L, Binkert C, Fischli W, Weller T, Bur D. Boss C, et al. Among authors: weller t. ChemMedChem. 2006 Dec;1(12):1341-5. doi: 10.1002/cmdc.200600223. ChemMedChem. 2006. PMID: 17091526 No abstract available.
Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.
Le Bihan A, de Kanter R, Angulo-Barturen I, Binkert C, Boss C, Brun R, Brunner R, Buchmann S, Burrows J, Dechering KJ, Delves M, Ewerling S, Ferrer S, Fischli C, Gamo-Benito FJ, Gnädig NF, Heidmann B, Jiménez-Díaz MB, Leroy D, Martínez MS, Meyer S, Moehrle JJ, Ng CL, Noviyanti R, Ruecker A, Sanz LM, Sauerwein RW, Scheurer C, Schleiferboeck S, Sinden R, Snyder C, Straimer J, Wirjanata G, Marfurt J, Price RN, Weller T, Fischli W, Fidock DA, Clozel M, Wittlin S. Le Bihan A, et al. Among authors: weller t. PLoS Med. 2016 Oct 4;13(10):e1002138. doi: 10.1371/journal.pmed.1002138. eCollection 2016 Oct. PLoS Med. 2016. PMID: 27701420 Free PMC article.
Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.
Bezençon O, Bur D, Weller T, Richard-Bildstein S, Remen L, Sifferlen T, Corminboeuf O, Grisostomi C, Boss C, Prade L, Delahaye S, Treiber A, Strickner P, Binkert C, Hess P, Steiner B, Fischli W. Bezençon O, et al. Among authors: weller t. J Med Chem. 2009 Jun 25;52(12):3689-702. doi: 10.1021/jm900022f. J Med Chem. 2009. PMID: 19358611
Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.
Bolli MH, Marfurt J, Grisostomi C, Boss C, Binkert C, Hess P, Treiber A, Thorin E, Morrison K, Buchmann S, Bur D, Ramuz H, Clozel M, Fischli W, Weller T. Bolli MH, et al. Among authors: weller t. J Med Chem. 2004 May 20;47(11):2776-95. doi: 10.1021/jm031115r. J Med Chem. 2004. PMID: 15139756
New classes of potent and bioavailable human renin inhibitors.
Remen L, Bezençon O, Richard-Bildstein S, Bur D, Prade L, Corminboeuf O, Boss C, Grisostomi C, Sifferlen T, Strickner P, Hess P, Delahaye S, Treiber A, Weller T, Binkert C, Steiner B, Fischli W. Remen L, et al. Among authors: weller t. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6762-5. doi: 10.1016/j.bmcl.2009.09.104. Epub 2009 Oct 1. Bioorg Med Chem Lett. 2009. PMID: 19853442
Bis-sulfonamides as endothelin receptor antagonists.
Boss C, Bolli MH, Weller T, Fischli W, Clozel M. Boss C, et al. Among authors: weller t. Bioorg Med Chem Lett. 2003 Mar 10;13(5):951-4. doi: 10.1016/s0960-894x(02)01083-1. Bioorg Med Chem Lett. 2003. PMID: 12617928
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, Iglarz M, Meyer S, Rein J, Rey M, Treiber A, Clozel M, Fischli W, Weller T. Bolli MH, et al. Among authors: weller t. J Med Chem. 2012 Sep 13;55(17):7849-61. doi: 10.1021/jm3009103. Epub 2012 Aug 16. J Med Chem. 2012. PMID: 22862294
219 results